Radiotherapy for Localized and Locally Advanced Prostate Cancer

  • Alberto BossiEmail author
  • Warren R. Bacorro
  • Gabriele Coraggio
Living reference work entry

Latest version View entry history


Radiotherapeutic management encompasses all stages of prostate cancer. Conformal and intensity-modulated techniques have made possible dose-escalated external radiotherapy improving survival outcomes in localized disease and reducing toxicity in the postoperative adjuvant setting. Stereotactic techniques, under rigorous conditions, permit moderate and extreme hypofractionation which shortens the overall treatment time. In the curative setting, this can be a tool for dose escalation by taking advantage of the radiobiologic properties of prostate cancer. In the palliative setting, this allows for shorter regimens and, more importantly, re-irradiation. Finally, with the advent of transrectal ultrasonography, prostate brachytherapy has emerged as a versatile tool, either as a monotherapy in the treatment of low- or intermediate-risk disease, as a boost to external radiotherapy in high-risk disease, or as salvage treatment.


  1. Abdel-Wahab M, et al. Second primary cancer after radiotherapy for prostate cancer—a SEER analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:58–68.CrossRefGoogle Scholar
  2. Alicikus ZA, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;117:1429–37.CrossRefGoogle Scholar
  3. Al-Mamgani A, et al. Update of Dutch multicenter dose escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–8.CrossRefGoogle Scholar
  4. Aluwini S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16(3):274–83.CrossRefGoogle Scholar
  5. Arcangeli G, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79:1013–21.CrossRefGoogle Scholar
  6. Asbell SO, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys. 1988;15:1307.CrossRefGoogle Scholar
  7. Ash D, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57(3):315–21.CrossRefGoogle Scholar
  8. Beckendorf V, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63.CrossRefGoogle Scholar
  9. Bolla M, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066.CrossRefGoogle Scholar
  10. Brenner DJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88(2):398–406.CrossRefGoogle Scholar
  11. Chen CP, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013;86(2):324–9.CrossRefGoogle Scholar
  12. Chung H. Focal salvage HDR brachytherapy for the treatment of prostate cancer (NCT01583920). 2016. Retrieved from
  13. Chung H. Pilot study of whole gland salvage HDR prostate brachytherapy for locally recurrent prostate cancer (NCT02560181). 2016. Retrieved from
  14. Cox JD, et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.CrossRefGoogle Scholar
  15. D’Amico AV, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289.CrossRefGoogle Scholar
  16. Davis BJ, et al. American brachytherapy society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11:6–19.CrossRefGoogle Scholar
  17. Dearnaley DP, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–87.CrossRefGoogle Scholar
  18. Dearnaley DP, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15:464.CrossRefGoogle Scholar
  19. Denham JW, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12:451.CrossRefGoogle Scholar
  20. Gomez-Veiga F, et al. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int. 2012;109(s1):17–21.CrossRefGoogle Scholar
  21. Guerif S, et al. Focal salvage HDR brachytherapy for local prostate cancer recurrence after primary radiation therapy: early experience of prospective study. Brachytherapy. 2014;13:S116–7.CrossRefGoogle Scholar
  22. Hamdy FC, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.Google Scholar
  23. Heemsbergen WD, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110:104.CrossRefGoogle Scholar
  24. Hoskin PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217–22.CrossRefGoogle Scholar
  25. Hoskin PJ, et al. GEC/ESTRO recommendations on high dose rate afterloading. Radiol Oncol. 2013;107:325–32.CrossRefGoogle Scholar
  26. Hsu CC, et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(2):370–7.CrossRefGoogle Scholar
  27. Hu K, et al. Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;40:783–6.CrossRefGoogle Scholar
  28. James ND, et al. Impact of node status and radiotherapy on failure-free survival in patients with newly-diagnosed non-metastatic prostate cancer: data from >690 patients in the control arm of the STAMPEDE trial. Int J Radiat Oncol Biol Phys. 2014;90:S13.CrossRefGoogle Scholar
  29. Jo Y, et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int. 2012;109(6):835–9.CrossRefGoogle Scholar
  30. King CR, et al. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104–11.CrossRefGoogle Scholar
  31. King CR, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiol Oncol. 2013;109:217–21.CrossRefGoogle Scholar
  32. Koontz BF, et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015;68(4):683–91.CrossRefGoogle Scholar
  33. Kuban D, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol. 2008;70(1):67–74.CrossRefGoogle Scholar
  34. Kuban DA, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79:1310.CrossRefGoogle Scholar
  35. Kupelian PA, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol. 2004;58:25–33.CrossRefGoogle Scholar
  36. Lawton CA, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646.CrossRefGoogle Scholar
  37. Lee B, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67(4):1106–12.CrossRefGoogle Scholar
  38. Leibel SA, et al. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys. 1994;28:7.CrossRefGoogle Scholar
  39. Locke J, et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy. A prospective study. Int J Radiat Oncol Biol Phys. 2002;52(3):712–9.CrossRefGoogle Scholar
  40. Losa A, et al. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology. 2003;62:1068–72.CrossRefGoogle Scholar
  41. Marks LB, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.CrossRefGoogle Scholar
  42. Michalski J, et al. Clinical outcome of patients treated with 3D conformal radiation therapy 3D-CRT for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012a;83:e363–70.CrossRefGoogle Scholar
  43. Michalski JM, et al. Prostate cancer. In: Joel T, Gunderson LL, editors. Clinical radiation oncology 3e. Philadelphia: Elsevier Saunders; 2012b. p. 1070–1.Google Scholar
  44. Morris WJ, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2016;98(2):275–85.CrossRefGoogle Scholar
  45. Mottet N, et al. EAU – ESTRO – SIOG guidelines on prostate cancer. European Association of Urology; 2016.Google Scholar
  46. Nag SC. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2001;51:1422–30.CrossRefGoogle Scholar
  47. National Cancer Comprehensive Network. NCCN guidelines version 3.2016 prostate cancer. 2016.Google Scholar
  48. Niehoff P, et al. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Brachytherapy. 2005;4(2):141–5.CrossRefGoogle Scholar
  49. Peters M, et al. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol. 2014;112(1):77–82.CrossRefGoogle Scholar
  50. Peters M, et al. Urethral and bladder dosimetry of total and focal salvage iodine-125 prostate brachytherapy: late toxicity and dose constraints. Radiother Oncol. 2015;117(2):262–9.CrossRefGoogle Scholar
  51. Peters M, et al. Rectal dose constraints for salvage iodine-125 prostate brachytherapy. Brachytherapy. 2016;15(1):85–93.CrossRefGoogle Scholar
  52. Pilepich MV, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285.CrossRefGoogle Scholar
  53. Pommier P, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366.CrossRefGoogle Scholar
  54. Roach M, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585.CrossRefGoogle Scholar
  55. Robinson JW, et al. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:1063–8.CrossRefGoogle Scholar
  56. Tetreault-Laflamme A, et al. Options for salvage of radiation failures for. Semin Radiat Oncol. 2016;27:67–78.CrossRefGoogle Scholar
  57. Tharp M, et al. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy. 2008;7(3):231–6.CrossRefGoogle Scholar
  58. Traudt K, et al. Prostate cancer recurrence after radical prostatectomy. Urology. 2011;77:1416–9.CrossRefGoogle Scholar
  59. Wilkins A, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2015;16:1605–16.CrossRefGoogle Scholar
  60. Yamada Y, et al. A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy. 2014;13(2):111–6.CrossRefGoogle Scholar
  61. Yeoh EE, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1072–83.CrossRefGoogle Scholar
  62. Zelefsky MJ, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases free survival outcomes. Eur Urol. 2011;60:1133–9.CrossRefGoogle Scholar
  63. Zietman AL, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–9.CrossRefGoogle Scholar
  64. Zietman A, et al. A randomized trial comparing conventional-dose with conformal radiation therapy high-dose in early stage adenocarcinoma of the prostate. Long-term results from Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09. J Clin Oncol. 2010;28:1106–11.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alberto Bossi
    • 1
    Email author
  • Warren R. Bacorro
    • 2
    • 4
  • Gabriele Coraggio
    • 3
  1. 1.Department of Radiation Oncology, Genito Urinary UnitGustave RoussyVillejuifFrance
  2. 2.Department of Radiation OncologyGustave RoussyVillejuifFrance
  3. 3.Departement of Radiation Oncology Genitourinary UnitHenry MONDOR Hospital APHPCreteilFrance
  4. 4.Brachytherapy Unit, Department of Radiation OncologyUniversity of Santo Tomas Hospital - Benavides Cancer InstituteManilaPhilippines

Section editors and affiliations

  • Thomas Steuber
    • 1
  1. 1.Martini-Klinik am UKE GmbHHamburgGermany

Personalised recommendations